These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34474665)

  • 1. Investigating the effect of an identified mutation within a critical site of PAS domain of WalK protein in a vancomycin-intermediate resistant Staphylococcus aureus by computational approaches.
    Baseri N; Najar-Peerayeh S; Bakhshi B
    BMC Microbiol; 2021 Sep; 21(1):240. PubMed ID: 34474665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mutation of walK confers vancomycin-intermediate resistance in methicillin-susceptible Staphylococcus aureus.
    Zhu J; Liu B; Shu X; Sun B
    Int J Med Microbiol; 2021 Feb; 311(2):151473. PubMed ID: 33445057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.
    Howden BP; McEvoy CR; Allen DL; Chua K; Gao W; Harrison PF; Bell J; Coombs G; Bennett-Wood V; Porter JL; Robins-Browne R; Davies JK; Seemann T; Stinear TP
    PLoS Pathog; 2011 Nov; 7(11):e1002359. PubMed ID: 22102812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A vancomycin resistance-associated WalK(S221P) mutation attenuates the virulence of vancomycin-intermediate Staphylococcus aureus.
    Rao Y; Peng H; Shang W; Hu Z; Yang Y; Tan L; Li M; Zhou R; Rao X
    J Adv Res; 2022 Sep; 40():167-178. PubMed ID: 36100324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of subinhibitory concentration of chlorhexidine on the evolution of vancomycin-intermediate Staphylococcus aureus and the induction of mutations in walKR and vraTSR systems.
    Baseri N; Najar-Peerayeh S; Bakhshi B
    Infect Genet Evol; 2021 Jan; 87():104628. PubMed ID: 33171303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
    Shoji M; Cui L; Iizuka R; Komoto A; Neoh HM; Watanabe Y; Hishinuma T; Hiramatsu K
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3870-81. PubMed ID: 21628539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression.
    McEvoy CR; Tsuji B; Gao W; Seemann T; Porter JL; Doig K; Ngo D; Howden BP; Stinear TP
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3240-9. PubMed ID: 23629723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cervimycin-Resistant Staphylococcus aureus Strains Display Vancomycin-Intermediate Resistant Phenotypes.
    Dietrich A; Steffens U; Gajdiss M; Boschert AL; Dröge JK; Szekat C; Sass P; Malik IT; Bornikoel J; Reinke L; Maček B; Franz-Wachtel M; Nieselt K; Harbig T; Scherlach K; Brötz-Oesterhelt H; Hertweck C; Sahl HG; Bierbaum G
    Microbiol Spectr; 2022 Oct; 10(5):e0256722. PubMed ID: 36173303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.
    Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and genotypic changes of Staphylococcus aureus in the presence of the inappropriate concentration of chlorhexidine gluconate.
    Baseri N; Najar-Peerayeh S; Bakhshi B; Campanile F
    BMC Microbiol; 2022 Apr; 22(1):100. PubMed ID: 35418037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an Amplicon Nanopore Sequencing Strategy for Detection of Mutations Conferring Intermediate Resistance to Vancomycin in Staphylococcus aureus Strains.
    Moller AG; Petit RA; Davis MH; Read TD
    Microbiol Spectr; 2023 Feb; 11(1):e0272822. PubMed ID: 36688645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
    Matsuo M; Cui L; Kim J; Hiramatsu K
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association.
    Alam MT; Petit RA; Crispell EK; Thornton TA; Conneely KN; Jiang Y; Satola SW; Read TD
    Genome Biol Evol; 2014 Apr; 6(5):1174-85. PubMed ID: 24787619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WalK(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108.
    Peng H; Hu Q; Shang W; Yuan J; Zhang X; Liu H; Zheng Y; Hu Z; Yang Y; Tan L; Li S; Hu X; Li M; Rao X
    J Antimicrob Chemother; 2017 Apr; 72(4):1006-1013. PubMed ID: 27999059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VraR Binding to the Promoter Region of
    Dai Y; Chang W; Zhao C; Peng J; Xu L; Lu H; Zhou S; Ma X
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.
    Matsuo M; Hishinuma T; Katayama Y; Cui L; Kapi M; Hiramatsu K
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4188-95. PubMed ID: 21746940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of mutations in hVISA isolates on decreased susceptibility to vancomycin, through population analyses profile - area under curve (PAP-AUC).
    Silveira ACO; Caierão J; Silva CI; Anzai EK; McCulloch JA; d'Azevedo PA; Sincero TCM
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114854. PubMed ID: 31366440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of amino acid changes in the yvqF, vraSR, graSR, and tcaRAB genes from vancomycin intermediate resistant Staphylococcus aureus.
    Yoo JI; Kim JW; Kang GS; Kim HS; Yoo JS; Lee YS
    J Microbiol; 2013 Apr; 51(2):160-5. PubMed ID: 23625215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.
    Saito M; Katayama Y; Hishinuma T; Iwamoto A; Aiba Y; Kuwahara-Arai K; Cui L; Matsuo M; Aritaka N; Hiramatsu K
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5024-35. PubMed ID: 24841271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of RNAIII in vancomycin-intermediate Staphylococcus aureus strains regardless of the presence of agr mutation.
    Park C; Shin NY; Byun JH; Shin HH; Kwon EY; Choi SM; Kim SH; Kwon JC; Park SH; Choi JH; Yoo JH; Yoo JI; Chung GT; Lee DG
    J Med Microbiol; 2012 Mar; 61(Pt 3):345-352. PubMed ID: 22016559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.